Nektar Therapeutics (NKTR) EPS Estimated At $-0.43 on May, 8

April 16, 2018 - By Sheila Anderson

Nektar Therapeutics (NASDAQ:NKTR) Corporate Logo
Big Money Sentiment decreased to 1.19 in 2017 Q4. It has change of 0.21, from 2017Q3’s 1.4. The ratio turned negative due to Nektar Therapeutics positioning: 18 sold and 82 reduced. 65 funds bought stakes and 54 increased stakes. Investors holded 148.76 million in 2017Q3 but now own 150.36 million shares or 1.08% more.
Sectoral Asset Mgmt stated it has 0.88% in Nektar Therapeutics (NASDAQ:NKTR). Citigroup stated it has 1,759 shs or 0% of all its holdings. Panagora Asset reported 636,245 shs. Qs Invsts Limited Liability Com holds 0% or 3,612 shs in its capital. Rothschild Asset Mngmt holds 627,279 shs or 0.4% of its capital. Td Asset Mgmt Incorporated stated it has 22,800 shs. Columbus Circle holds 0.27% of its capital in Nektar Therapeutics (NASDAQ:NKTR) for 242,114 shs. Texas Permanent School Fund stated it has 0.08% in Nektar Therapeutics (NASDAQ:NKTR). Parkside Comml Bank invested in 0% or 91 shs. Amalgamated Retail Bank holds 21,775 shs or 0.04% of its capital. Moreover, Kennedy Capital has 0.3% invested in Nektar Therapeutics (NASDAQ:NKTR). Moreover, Wellington Management Ltd Liability Partnership has 0.03% invested in Nektar Therapeutics (NASDAQ:NKTR) for 2.02 million shs. Moreover, Swiss Bancorp has 0.02% invested in Nektar Therapeutics (NASDAQ:NKTR) for 266,300 shs. Winslow Evans And Crocker holds 300 shs or 0.01% of its capital. Coldstream holds 0.04% or 6,898 shs in its capital.

Nektar Therapeutics had 17 sales and 0 buys since December 13, 2017. This’s net activity of $66.98 million. Doberstein Stephen K sold $14.89 million worth of Nektar Therapeutics (NASDAQ:NKTR) on Friday, April 6. 83,333 shs valued at $6.32 million were sold by ROBIN HOWARD W on Monday, January 22. On Friday, February 16 a trade for 4,879 shs valued at $404,664 was made by Nicholson John. KUEBLER CHRISTOPHER A had sold 40,000 shs worth $3.90 million. On Friday, February 16 the insider Thomsen Jillian B. sold $211,082. Another trade for 30,000 shs valued at $3.05 million was sold by Lingnau Lutz.

Earnings report for Nektar Therapeutics (NASDAQ:NKTR) is awaited On May, 8., according to Zacks. The EPS diference is $0.01 or 2.38 % down from last years number. Previous year: $-0.42; Analysts forcast: $-0.43. 207.14 % negative EPS growth is what analysts predict. $-0.14 EPS was announced for last [previous quarter]. The stock decreased 7.00% or $7.03 during the last trading session, reaching $93.47.Nektar Therapeutics is uptrending after having risen 347.01% since April 17, 2017. NKTR has 7.15 million volume or 131.24% up from normal. NKTR outperformed the S&P 500 by 335.46%.

Nektar Therapeutics (NASDAQ:NKTR) Ratings Coverage

In total 7 analysts cover Nektar Therapeutics (NASDAQ:NKTR). “Buy” rating has 7, “Sell” are 0, while 0 are “Hold”. 100% are bullish. 12 are the (NASDAQ:NKTR)’s analyst reports since October 18, 2017 according to StockzIntelligence Inc. On Monday, November 13 the stock of Nektar Therapeutics (NASDAQ:NKTR) earned “Buy” rating by Roth Capital. The stock rating was maintained by Jefferies with “Buy” on Wednesday, November 8. The stock rating was maintained by Canaccord Genuity with “Buy” on Wednesday, January 10. On Wednesday, October 18 the company was maintained by Jefferies. On Friday, April 13 the firm has “Overweight” rating by PiperJaffray given. On Friday, April 6 the company was maintained by Mizuho. On Monday, April 2 H.C. Wainwright reinitiated the shares of NKTR in report with “Buy” rating. On Monday, April 9 the firm has “Buy” rating by Cowen & Co given. On Thursday, November 9 the stock has “Buy” rating by Canaccord Genuity. On Thursday, March 29 Mizuho maintained the shares of NKTR in report with “Buy” rating.

Nektar Therapeutics develops drug candidates based on its PEGylation and polymer conjugate technology platforms in the United States.The firm is worth $15.04 billion. The Company’s product pipeline includes drug candidates in therapeutic areas comprising cancer, auto-immune disease, and chronic pain.Currently it has negative earnings. The firm offers MOVANTIK, an oral peripherally-acting opioid antagonist for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain; MOVENTIG for the treatment of opioid-induced constipation in adult patients who have an inadequate response to laxatives; and ADYNOVATE for use in treating Hemophilia A.

Nektar Therapeutics (NASDAQ:NKTR) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.